Groups

Research Focus

Medicine; Associate Attending

Recent additions – View all

1. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, version 2.2019: Featured updates to the NCCN Guidelines

   Journal Article

   Wierda, W. G.; Byrd, J. C.; Abramson, J. S.; Bilgrami, S. F.; Bociek, G.; Brander, D.; Brown, J.; Chanan-Khan, A. A.; Chavez, J. C.; Coutre, S. E.; more...
   Journal of the National Comprehensive Cancer Network (2019)

   Fulltext@MSK | Save
2. Combinations or sequences of targeted agents in CLL: Is the whole greater than the sum of its parts (Aristotle, 360 BC)?

   Journal Article

   Yazdy, M. S.; Mato, A. R.; Cheson, B. D.
   Blood (2019)

   Fulltext@MSK | Save
3. A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3Kδ inhibitor therapy

   Meeting Abstract

   Mato, A. R.; Schuster, S. J.; Lamanna, N.; Flinn, I.; Barrientos, J. C.; Kambhampati, S.; Cheson, B. D.; Barr, P. M.; Pagel, J. M.; Reeves, J. A.; more...
   Journal of Clinical Oncology (2018)

   Fulltext@MSK | Save